References
- Waltenberg J, Miyazono K, Funa K, Wanders A, Fellström B, Heldin CH. Transforming growth factor-β and organ transplantation. Transplant Proc 1993; 25: 2038–2040
- Czarniecki CW, Chiu HH, Wong G HW, McCabe SM, Palladino MA. Transforming growth factor-β1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol 1988; 140: 4217–4223
- Gamble JR, Vadas MA. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-β. Science 1988; 242: 97–99
- Kehrl JH, Roberts AB, Wakefield LM. Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes. J Immunol 1986; 137: 3855–3860
- Kehrl JH, Wakefield LM, Roberts AB. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986; 163: 1037–1050
- Rook AH, Kehrl JH, Wakefield LM. Effects of transforming growth factor β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986; 136: 3916–3920
- Tsunawaki S, Sporn M, Ding A. Deactivation of macrophages by transforming growth factor-β. Nature 1988; 334: 260–262
- Connor TB, Jr, Roberts AB, Sporn MB. Correlation of fibrosis and transforming growth factor-β type 2 levels in the eye. J Clin Invest 1989; 83: 1661–1666
- Streilein JW, Wilbanks GA, Taylor A. Eye derived cytokines and the immuno-suppressive intraocular microenvironment: a review. Curr Eye Res 1992; 41–47, 11 suppl
- De Boer JH, van Haren M AC, De Vries-Knoppert W AEJ. Analysis of IL-6 levels in human vitreous fluid obtained from uveitis patients, patients with proliferative intraocular disorders and eye bank eyes. Curr Eye Res 1992; 181–186, 11 suppl
- Franks WA, Limb GA, Stanford MR, Ogilvie J, Wolstencroft RA, Chignell AH, Dumonde DC. Cytokines in human ocular inflammation. Curr Eye Res 1992; 187–191, 11 suppl
- Williams KA, Sawyer M, Alfrich SJ, Joseph L, White M, Coster DJ, Mahmood M. First report of the Australian corneal graft registry. Austr New Zeal J Ophthalmol 1987; 15: 291–302
- Zhou D, Munster A, Winchurch RA. Pathologic concentrations of interleukin 6 inhibit T cell responses via induction of activation of TGF-β. FASEB J 1991; 5: 2582–2585
- Völker-Dieben HJ, D'Amaro J. Corneal transplantation: a single center experience. Clinical Transplants, P Terasaki. UCLA Ti Typing Laboratory, Los Angeles 1988; 249–261
- De Boer JH, Limpens J, Orengo-Nania S, De Jong P TVM, La Heij E, Kijlstra A. Low mature TGF-β2 levels in aqueous humor during uveitis. Invest Ophthalmol Vis Sci 1994; 35: 3702–3710
- Rocha G, Baines MG, Deschênes J, Duclos AJ, Antecka E. Transforming growth factor-β in aqueous humor during experimentally induced uveitis. Ocular Immunol Inflamm 1993; 1: 343–355
- Granstein RD, Staszewski R, Knisely E, Zeira E, Nazareno R, Latina M, Albert DM. Aqueous humor contains transforming growth factor-β and a small (<3500 Daltons) inhibitor of thymocyte proliferation. J Immunol 1990; 144: 3021–3027
- Musso T, Espinoza-Delgado I, Pulkki K, Gabriele LG, Longo DL, Varesio L. Transforming growth factor β downregulates interleukin-1 (IL-1)-induced IL-6 production by human monocytes. Blood 1990; 76: 2466–2469
- Ranges GE, Figari IS, Espevik T, Palladino MA. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J Exp Med 1987; 166: 991–998
- Andres JL, Stanley K, Cheifetz S. Massagué J. Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-β. J Cell Biol 1989; 109: 3137–3145
- Lamarre J, Wollenberg GK, Gonias SL, Hayes MA. Biology of disease: Cytokine binding and clearance properties of proteinase-activated α2-macroglobulins. Lab Invest 1991; 65: 3–14
- James K. Interactions between cytokines and α2-macroglobulin. Immunol Today 1990; 11: 163–166